Media stories about Fortress Biotech (NASDAQ:FBIO) have been trending somewhat negative recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fortress Biotech earned a news sentiment score of -0.02 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.9561747130402 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Fortress Biotech (FBIO) Issues Quarterly Earnings Results (americanbankingnews.com)
- Fortress Biotech beats by $0.09, beats on revenue (seekingalpha.com)
- Fortress Biotech: 2Q Earnings Snapshot (finance.yahoo.com)
- Fortress Biotech (FBIO) Reports Q2 Loss, Tops Revenue Estimates (finance.yahoo.com)
- Fortress Biotech Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights (finance.yahoo.com)
Fortress Biotech traded down $0.04, hitting $2.09, on Friday, MarketBeat.com reports. 155,089 shares of the company’s stock traded hands, compared to its average volume of 240,059. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.52 and a quick ratio of 2.52. Fortress Biotech has a 1 year low of $1.41 and a 1 year high of $5.54. The stock has a market cap of $112.68 million, a PE ratio of -1.30 and a beta of 0.10.
Several analysts have issued reports on the company. Zacks Investment Research downgraded Fortress Biotech from a “hold” rating to a “sell” rating in a report on Wednesday, May 16th. HC Wainwright set a $11.00 target price on Fortress Biotech and gave the company a “buy” rating in a research note on Friday. ValuEngine cut Fortress Biotech from a “buy” rating to a “hold” rating in a research note on Monday, July 16th. Finally, JMP Securities set a $11.00 target price on Fortress Biotech and gave the company a “buy” rating in a research note on Monday, May 21st. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $10.67.
Fortress Biotech Company Profile
Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States.
Featured Article: How to Use the New Google Finance Tool
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.